Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)
Key takeaways
- JNJ beats Q3 earnings, lifts guidance, but faces significant charges from litigation and acquisitions that will weigh on 2027 earnings.
- Adjusted earnings Q3 2026: $2.59 per share
- Sales Q3 2026: $25.39 billion
- GAAP earnings Q3 2026: 9 cents per share
What happened
Johnson & Johnson (JNJ) reported Q3 2026 earnings that beat estimates, with adjusted earnings of $2.59 per share versus a consensus of $2.53. Sales rose 5.9% to $25.39 billion, topping the $25.25 billion consensus. The company raised its full‑year sales outlook to $101 billion‑$101.40 billion and adjusted earnings guidance to $11.05‑$11.15 per share. The results were impacted by $7 billion in charges from a talc litigation settlement, the acquisition of Firefly Bio, and a collaboration with…
Why it matters
The beat signals stronger-than‑expected performance in Johnson & Johnson’s core oncology and immunology businesses, reinforcing its ambition to become the world’s leading oncology company by 2030. The guidance lift indicates confidence in continued revenue growth, while the disclosed impact of the Firefly and Sail…
Short-term and longer-term
Short-term. JNJ shares fell 5.44% to $249.38 after the announcement, reflecting short‑term volatility around the earnings beat and guidance lift.
Longer-term. The guidance upgrade and oncology focus reinforce JNJ’s long‑term value proposition, positioning it as a leading oncology player with projected sales over $50 billion by 2030.